ArticleJournal of neurology2016
Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.
Article in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.CNS drugs · 2026Pooled it
- Exercise and Pain in Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, and Stroke: A Systematic Review and Meta-analysis.Sports medicine (Auckland, N.Z.) · 2026Pooled it
- Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study.British journal of clinical pharmacology · 2018Trial
- Utility of Multi-Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from Pseudoexacerbation.Neurology and therapy · 2026Article
- Combination Versus Monotherapy in Acute Anti-LGI1 Encephalitis: A Real-World Dose Optimization Analysis.Neuropsychopharmacology reports · 2026Article
- Cellular Immunotherapies for Multiple Sclerosis: Mechanistic Insights and Clinical Advances.International journal of molecular sciences · 2026Review
- Efgartigimod-rituximab sequential therapy in Anti-NMDAR encephalitis: real-world evidence for a novel salvage-maintenance strategy.Journal of neurology · 2025Article
- Exploring the neuroprotective potential of naringin following spinal cord injury in rats: improving sensory and motor function through combating inflammation and oxidative stress.Frontiers in pharmacology · 2025Article
- Stem cell therapies: a new era in the treatment of multiple sclerosis.Frontiers in neurology · 2024Review
- Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy.Journal of clinical medicine · 2023Article
- Heat-Shock Proteins Can Potentiate the Therapeutic Ability of Cryopreserved Mesenchymal Stem Cells for the Treatment of Acute Spinal Cord Injury in Dogs.Stem cell reviews and reports · 2022Article
- Safety of Intravenous Methylprednisolone in Refractory and Severe Pediatric Uveitis.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- S100B inhibition protects from chronic experimental autoimmune encephalomyelitis.Brain communications · 2022Article
- HSP70 alleviates spinal cord injury by activating the NF-kB pathway.Journal of musculoskeletal & neuronal interactions · 2021Article
- Stress and the "extended" autonomic system.Autonomic neuroscience : basic & clinical · 2021Review
- The extended autonomic system, dyshomeostasis, and COVID-19.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2020Review
- Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group.The Journal of rheumatology · 2019Article
- Temperature sensitivity in multiple sclerosis: An overview of its impact on sensory and cognitive symptoms.Temperature (Austin, Tex.) · 2018Review
- Does vitamin C have the ability to augment the therapeutic effect of bone marrow-derived mesenchymal stem cells on spinal cord injury?Neural regeneration research · 2017Article
- Effects of erythropoietin and methylprednisolone on AQP4 expression in astrocytes.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a prospective multi-center observational study, we evaluated the frequency, severity, and impact on activities of daily living (ADL) of adverse effects (AEs) of high-dose intravenous methylprednisolone (IVMP) in relapsing remitting multiple sclerosis (MS) patients with a relapse. Online self-report questionnaires stating IVMP's most common AEs were completed at baseline, the 2nd day of treatment, and 1 day and 1 week after treatment. Eighty-five patients were included, 66 completed the baseline questionnaire, and 59 completed at least one post-baseline questionnaire. Patients reported on average 4 (median) AEs; two (3.4 %) reported no AE. Most frequent was change in taste (61 %), facial flushing (61 %), sick/stomach pain (53 %), sleep disturbance (44 %), appetite change (37 %), agitation (36 %), and behavioral changes (36 %). Of all AEs, 34.3 % were severe and 37.9 % impacted on ADL. A 3-day course resulted in 4 (median) AEs and a 5-day course in 7. All patients with high disease impact had two or more AEs, compared with 79 % of those with low impact (p < 0.01). Of patients with high disability, 45 % had severe AEs, compared with 16 % of those with low disability. Severe central nervous system (CNS)-related AEs occurred two times more frequently in patients with high disease impact, and two-and-a-half times more frequently in patients with high disability. Therefore, in virtually all patients, high-dose IVMP leads to AEs, with about one of three AEs being severe with impact on ADL. Patients with high disease impact or high disability may experience more (severe) AEs, due to a higher occurrence of severe CNS-related AEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.